Title：

Osteoporosis Genetic Risk Prediction Using Bone Mineral Density Polygenic

Scores in Japanese: TMM CommCohort Study

Author：Yayoi Otsuka-Yamasaki, PhD, DVM[1,2]*, Yoichi Sutoh, PhD[1,2], Tsuyoshi Hachiya,

PhD[1,2], Motoki Nakao, PhD, MD[1,3,4], Shiori Minabe, PhD[1,2], Shohei Komaki, PhD[1,2], Hideki

Ohmomo, PhD[1,2], Makoto Sasaki,PhD, MD[1,5], and Atsushi Shimizu, PhD[1,2].

[1] Iwate Tohoku Medical Megabank Organization, Disaster Reconstruction Center, Iwate

Medical University, 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan

[2] Division of Biomedical Information Analysis, Institute for Biomedical Sciences, Iwate

Medical University, 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan

[3] Department of Pharmacology, School of Medicine, Iwate Medical University, 1-1-1, Idaidori,

Yahaba 028-3694, Iwate, Japan

[4] Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of

Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Hokkaido, Japan

[5] Division of Ultrahigh field MRI, Institute for Biomedical Sciences, Iwate Medical University,

1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan.

*Corresponding author; Yayoi Otsuka-Yamasaki

Iwate Tohoku Medical Megabank Organization, Disaster Reconstruction Center, Iwate

Medical University, 1-1-1, Idaidori, Yahaba 028-3694, Iwate, Japan

Tel; +81-011-651-5110

Mail to; yyayo@iwate-med.ac.jp

Data Availability

The QUS-derived T-score GWAS summary statistics are available at jMorp

(https://jmorp.megabank.tohoku.ac.jp/gwas-studies/TGA000015). Individual-level data are

not publicly available; access may be granted upon request and approval by the Information

Distribution Review Committee of the TMM Project.

Funding

This study was supported by the Tohoku Medical Megabank Project of AMED

(JP23tm0124006; JP21tm0424601) and JSPS KAKENHI (JP23K09696, YOY and AS).

Conflict of Interest

T.H. is a board member of Genome Analytics Japan, Inc. The other authors declare no

conflicts of interest associated with this manuscript.

Ethics Approval

Institutional Review Board of Iwate Medical University gave ethical approval for this work

(approval ID: HG H25-2).

Patient Consent:

Written informed consent was obtained from all participants.

Keywords (~ 5 words)

Osteoporosis, Polygenic score, Bone mineral density, Genome-wide association study

(GWAS), Japanese population

Abstract

Osteoporosis and related fractures are major health concerns in aging populations. We aimed to develop and validate a polygenic score (PGS) for osteoporosis in a Japanese population using heel quantitative ultrasound (QUS)–derived T-scores. Using genome-wide association study data from 12,371 participants in the Tohoku Medical Megabank Community-Based Cohort, we identified genome-wide significant loci, including *MBL2, TMEM135,* and *WNT16.* PGS models were constructed and evaluated using independent datasets for model selection (n = 1,419) and validation (n = 8,711). Adding the PGS to age and sex resulted in only a modest increase in discrimination (AUC = 0.664 to 0.728) but supported genetic risk stratification. Individuals in the lowest PGS quintile (bottom 20%, genetically high-risk) had an increased risk of osteoporosis (odds ratio (OR) = 1.22, 95% confidence interval (CI): 1.07–1.40), whereas those in the highest PGS quintile (top 20%, genetically low-risk) had a reduced risk (OR = 0.85, 95% CI: 0.71–0.98). Prospective analysis over a mean 3.4-year follow-up confirmed the gradient: the lowest-quintile (high-risk) group had a higher incidence rate ratio (IRR) than the intermediate group (IRR = 1.42, 95% CI: 1.17–1.73), whereas the highest-quintile (low-risk) group had a lower IRR (IRR = 0.70, 95% CI: 0.54–0.89). Age-stratified analyses revealed no statistically significant interaction between age and PGS in predicting osteoporosis, and no differences in the slope of age-related T-score declines across genetic risk groups. Observed T-scores in young adults (20–44 years) and extrapolation to age 20 suggested lower bone status around peak bone mass among genetically high-risk individuals. These findings indicate that a Japanese-specific PGS can stratify osteoporosis risk and may help identify individuals at elevated genetic risk earlier in adulthood.

79
Lay summaries

We developed a bone mineral density (BMD) genetic score in a large Japanese population

and tested whether it can predict osteoporosis. People with scores in the lowest 20% had a

higher risk, while those in the highest 20% had a lower risk, and this pattern persisted over

3.4 years of follow-up. The score was not related to how quickly bone density fell with age.

Analyses in young adults and projections to age 20 suggested that it mainly reflects

differences in peak bone mass, underscoring the importance of early identification and

prevention in people at high genetic risk.

Introduction

Osteoporosis and osteoporotic fractures are significant public health concerns associated with impaired activities of daily living, diminished quality of life, and elevated mortality rates.[1] In older adults, fractures frequently necessitate prolonged care, thereby imposing economic burdens, including elevated expenditures for medical care and long-term care services.[2,3] The estimated number of patients with osteoporosis in Japan is approximately 12.8 million, with approximately 193,400 hip fractures occurring annually.[4]

Bone mineral density (BMD) is widely used as an indicator of bone mass, with heritability (the contribution of genetic factors) estimated at 50–80%, indicating a significant influence of genetic factors.[3,5] Bone mass follows a characteristic life-course trajectory, with rapid accrual during childhood and puberty, reaching peak levels in the 20s, remaining relatively stable through midlife, and subsequently declining, particularly after menopause in women.[1,6] As 40–60% of adult bone mass is formed during puberty, peak bone mass is considered a key determinant of the lifelong risk of developing osteoporosis.[6] Achieving and maintaining a higher peak bone mass during growth has been reported to provide a protective effect against osteoporosis in later life.[1,6,7]

Advancements in genome-wide association studies (GWASs) have led to the identification of numerous variants associated with BMD and fracture risk.[5,8] Polygenic scores (PGS), derived from variants associated with BMD, have been developed to predict the genetic risk of osteoporosis and osteoporotic fractures.[5,9]

Recently, an estimated bone mineral density (eBMD) PGS derived from quantitative ultrasound (QUS) measurements was developed using data from the UK Biobank.[5,9] The eBMD-based PGS has been evaluated for its predictive accuracy for osteoporosis and fractures in multiple cohorts, as it shows a negative correlation with osteoporosis and fracture risk.[5,9,10] However, studies have consistently demonstrated that PGS derived from European populations exhibit reduced predictive performance in non-European populations, including East Asians.[10-12] To address this limitation, there is an urgent need to develop PGS models

tailored to non-Europeans, including East Asians.[13-17] Chen et al.[17] have tested the multi-

ancestry PGS, including Asians in a cohort of Taiwanese people, and demonstrated that it

has moderate efficacy, but its performance is not always optimal, and it emphasizes that the

development of population-specific PGS is essential in East Asian populations.

Concurrently, it has been shown that incorporating modifiable lifestyle factors into a

PGS framework may not only predict lifetime risk but also guide targeted prevention

strategies.[18] BMD is influenced by both basic and unchangeable environmental factors,

such as sex, age, and race, as well as modifiable factors such as calcium intake, smoking,

alcohol consumption, physical activity, and sun exposure.[6,19] Even individuals with a high

genetic risk for osteoporotic fractures can reduce their risk by adhering to healthy lifestyle

habits in European populations.[19]

In this study, we developed a PGS for QUS-derived T-score in a Japanese

population using data from the Tohoku Medical Megabank (TMM), the largest genome cohort

in Japan,[20–22] and evaluated its ability to predict osteoporosis risk. Using a longitudinal

design, we assessed genetic and environmental factors at baseline and followed participants

over time to capture incident osteoporosis. We stratified participants by PGS, examined its

joint effects with non-modifiable and modifiable risk factors, and evaluated its potential as a

tool to inform osteoporosis prevention strategies in Japan.

Materials and Methods

Study population

TMM Project Community-Based Cohort (TMM CommCohort) has been described

in previous studies.[20-22] Participants who visited the evaluation centers in Miyagi and Iwate

Prefectures, were grouped into two main cohorts: TMM18K and TMM9K, respectively. The

baseline survey was conducted from May 2013 to March 2016, and the secondary survey,

conducted 4 years after the baseline, was conducted from May 2017 to March 2020 as part

of the ongoing follow-up.

The two cohorts were further divided into four groups based on genotyping with the

Axiom Japonica Array v2 (JPAv2)[23,24] or NEO (JPANEO)[25] (TMM18K-JPAv2, TMM18K-

JPANEO, TMM9K-JPAv2, and TMM9K-JPANEO) (Figure 1 and Supplementary Table S1).

The TMM18K-JPAv2 cohort (n = 12,371) was used to perform QUS-derived T-score GWAS,

from which the variant weights for the PGS model were derived. The TMM9K-JPANEO cohort

(n = 1,419) was used to identify the best model for predicting osteoporosis. The TMM9K-

JPAv2 (n = 7,621) and TMM18K-JPANEO (n = 1,090) cohorts were used for subsequent

analyses. All four sample subgroups were independent of one another.

Phenotype definition and measurement

Calcaneal QUS measurements were performed using a Benus device (NIHON

KOHDEN, Tokyo, Japan). The device-derived calcaneal T-score was calculated using the

manufacturer's young-adult reference (ages 20–40 years). We classified participants as

having osteoporosis when the device-derived QUS T-score was ≤ −2.5. Fracture cases were

identified based on participants' self-reported history of fractures in the lumbar spine, femur,

wrist, or humerus as documented in the questionnaire. Other anthropometric and lifestyle

factors, including alcohol intake and smoking history, were obtained from self-reported

questionnaires administered at baseline.

Participants who had smoked at least 100 cigarettes in their lifetime were defined

as having a "smoking" status. "High alcohol intake" was defined as the consumption of ≥30

g of alcohol per day. "Physical inactivity" was defined as engaging in leisure-time physical

activity less than three times per week. "Obesity" was defined as a body mass index (BMI)

≥25 kg/m², calculated from height and weight measured at baseline, in accordance with the

local definition in Japan.[26]

Study participants and validation cohort definitions

To evaluate the predictive performance of PGS, we used two independent validation

cohorts: TMM9K-JPAv2 (validation cohort I) and TMM18K-JPANEO (validation cohort II). We

conducted cross-sectional and prospective analyses based on baseline and follow-up survey

data, respectively.

For the cross-sectional analysis, we excluded participants with (1) missing T-score

values at baseline, (2) extreme baseline T-scores (outside the range −4.0 to +4.0 SD), or (3)

missing essential covariates. The final sample included 7,609 participants in validation cohort

I and 1,061 participants in validation cohort II (Supplementary Table S1).

For the prospective analysis, additional exclusion criteria were applied: (1) no

participation in the follow-up survey; (2) baseline T-score ≤−2.5 SD; (3) history of fracture

(lumbar spine, femur, wrist, or humerus); (4) self-reported history of osteoporosis at follow-

up (due to unclear timing); and (5) extreme baseline T-scores (outside the range −4.0 to +4.0

SD). After these exclusions, the prospective subcohorts included 4,811 participants in

validation cohort I and 581 participants in validation cohort II (Supplementary Table S1).

Genotyping and imputation

It was described in previous studies that the genotyping was performed using either

JPAv2 [23,24] or NEO (JPANEO).[25] Participants with a call rate <0.95 and sex discrepancies

between genotypic and cohort data were excluded. Genotypes that failed to meet the quality

control criteria (call rate <0.99, Hardy–Weinberg equilibrium exact test P <1 × 10^{-5}, and minor

allele frequency <0.01) were also omitted. Pre-phasing and imputation were performed using

SHAPEIT2 (r837) and IMPUTE4 (r300.3) with 3.5KJPNv2 haplotype reference panels.[23,28,29]

Variant positions in the genome were based on the GRCh37 reference genome.

Genome-wide association analysis and annotations

To generate the PGS model, single nucleotide polymorphism weights were

estimated using a publicly available GWAS summary of TMM18K-JPAv2 from jMorp (ID:

TGA000015; https://jmorp.megabank.tohoku.ac.jp/). Additional methodological details are

available on the official website. In brief, GWAS was conducted with BOLT-LMM v2.3.2.[27]

Rank-based inverse normalization was applied to reduce the skewness and kurtosis in the

T-score distribution. Age, sex, and the first 11 principal components were included as fixed

effect covariates.

Annotation was performed using an in-house pipeline tailored to the Japanese

population. The ToMMo 3.5KJPNv2 reference panel[28] was used to assign allele frequency

information and dbSNP identifiers (rsIDs) to variants in the GWAS summary statistics. The

gnomAD v2.1 dataset[29] was additionally incorporated to ensure comprehensive rsID

annotation and facilitate cross-population comparisons. Regional association plots were

generated using LocusZoom (version 0.14.0).[30] Linkage disequilibrium patterns and proxy

variants were examined using LDproxy (LDlink, National Cancer Institute)[31] with the 1 KG

EAS reference panel.

PGS construction and selection

Candidate models were constructed as described previously using three methods:

LD pruning and thresholding (P+T), LDpred and polygenic risk score–continuous shrinkage

(PRS-CS).[26,32-34] For the P+T method, 24 models were generated using different LD-pruning

conditions using one of six parameters for p values (1, 0.5, 5×10^{-2}, 5×10^{-4}, 5×10^{-6}, and

5×10^{-8}) and one of four parameters of R^2 values (0.2, 0.4, 0.6, and 0.8). For LDpred, seven

models were generated for each Spearman's rank correlation (ρ) value (1, 0.3, 0.1, 0.03,

0.01, 0.003, and 0.001). For PRS-CS, six models were generated for each φ value (1×10^{-1},

1×10^{-2}, 1×10^{-4}, 1×10^{-6}, 1×10^{-8}, and "auto"). Individual PGSs were calculated using

PLINK 2.0 for each model and normalized to Z-scores.

In the selection step, TMM9K-JPANEO cohort was used as the dataset for model

selection. The model with the highest Spearman rank correlation coefficient (ρ) between the

age- and sex-adjusted T-scores and PGS Z-scores was selected.

Statistical analyses were performed using R (version 4.2.1). The receiver operating

characteristic (ROC) curve and area under the curve (AUC) for the PGS model was estimated

using the R package "pROC" (version 1.18.0). The AUCs between the models were

compared using DeLong's test.

PGS-based risk assessment and stratified analysis

The normalized PGS was divided into quintiles. Cross-sectional associations at

baseline were tested using linear regression for continuous outcomes and logistic regression

for binary outcomes, adjusting for sex and age. We additionally conducted stratified cross-

sectional analyses by baseline age (<65/≥65 years), sex, and major osteoporosis-related risk

factors (smoking, alcohol intake, physical activity, and obesity). For these stratified analyses,

participants were classified into three genetic risk groups: High (Q1), Intermediate (Q2–Q4),

and Low (Q5), using the Intermediate group as the reference category in all comparisons.

For prospective analyses, participants without osteoporosis at baseline were

followed up for an average of 3.4 years. Because the exact event dates were unavailable,

person-time was approximated using the midpoint method: incident cases contributed half of

the follow-up duration, while non-cases contributed the full duration. Incidence rates (IRs)

per 1,000 person-years and cumulative incidence were estimated by genetic risk group with

exact 95% confidence intervals (CI).

Results from the two validation cohorts were pooled using the R package "meta"

(version 6.2-1). Fixed-effect models were used for the primary meta-analyses. Between-

cohort heterogeneity was assessed using Cochran's Q test and the I² statistic. Random-

effects models (DerSimonian–Laird method) were also fitted, and in the presence of

substantial heterogeneity (Q test $P < 0.05$ or $I^2 > 50\%$), were additionally examined as

sensitivity analyses to confirm the robustness of the results.

Ethical considerations

This research was conducted in accordance with the ethical principles outlined in

the Declaration of Helsinki. All participants provided written informed consent prior to their

enrollment. The study protocol was approved by the Institutional Review Board of Iwate

Medical University (approval ID: HG H25-2). Analyses using individual-level genomic and

phenotypic data were performed on a secure, standalone computational platform operated

by the Tohoku Medical Megabank Organization (ToMMo) at Tohoku University (ToMMo

Supercomputer System URL; https://sc.megabank.tohoku.ac.jp/).

Data Availability

The QUS-derived T-score GWAS summary has been published in jMorp

(https://jmorp.megabank.tohoku.ac.jp/gwas-studies/TGA000015). 3.5KJPNv2 is also

available on the jMorp website with a web interface. Due to ethical considerations, including

the protection of participant privacy and prevention of unintended identification, individual-

level data from the TMM CommCohort Study are not publicly available. Access to these

cohorts may be granted upon request and is subject to approval by the Ethics Committee of

Iwate Medical University and the Materials and Information Distribution Review Committee

of the TMM Project. Researchers interested in accessing these datasets should contact the

corresponding author to initiate the request.

Results

Heritable factors for QUS-derived T-score

GWAS was conducted to identify variants associated with the T-score

(Supplementary Figure S1A). Variants in three independent loci were above the threshold for

the genome-wide significance ($P < 5 \times 10^{-8}$) (Table 1). There were 792 variants above the

suggestive line ($P < 1 \times 10^{-5}$) (Supplementary Table S2).

The three loci containing significant variants included genes that had been reported

in previous GWASs using QUS-derived T-scores as traits, such as Mannose Binding Lectin

2 (*MBL2*), Transmembrane Protein 135 (*TMEM135*), and *Wnt* Family Member 16 (*WNT16*)

[3,5,8] (Table 1). The UK Biobank GWAS summary statistics and GWAS catalog study

GCST006433[5] were used for comparison.

As shown in Table 1, at the *MBL2* locus, the lead variant in the Japanese GWAS

was rs71032654/rs200903639 (del(TA)$_9$CA > dup(TA)$_9$CA), a structural indel. Meanwhile,

neither rs71032654 nor rs7908619 was present in the UK Biobank summary statistics (Table

1). LocusZoom plots showed recombination hotspots exceeding 30 cM/Mb on either side of

rs71032654 (Supplementary Figure S1C). According to the LDproxy results,

rs71032654/rs200903639 showed only low LD with surrounding variants (maximum R^2 =

0.0687), suggesting that it may represent a distinct signal from previously known tagged

variants.

Variants in rs2451053 (C>T) in *TMEM135* and rs10254825 (A>G) in *WNT16* were

present in both the TMM and UK Biobank cohorts, indicating their similar biological effects

on BMD across populations.

Determination of the optimal PGS model for T-score measured with QUS

Based on the above GWAS summary, we constructed 37 candidate models to

calculate the PGS using three distinct methods (Figure 2A and Supplementary Table S3). We

found that the PGS model established by PRS-CS with φ set to "auto" which was composed

of 1,012,314 variants, showed the strongest correlation with T-score levels after adjusting for

age and sex (Spearman's ρ = 0.147, P = 2.94 × 10^{-8}). Therefore, this model was used for

subsequent validation analyses as the best model.

Linear regression analysis of baseline T-scores against normalized PGS, adjusted

for sex and age, revealed a significant positive association in validation cohorts I (Estimate

= 0.090, P = 1.19 × 10^{-15}, Adjusted R^2 = 0.237), and II (Estimate = 0.098, P = 0.001, Adjusted

R^2 = 0.204) (Figure 2B and Supplementary Table S4).

Predictive performance and association of T-score PGS with osteoporosis

To investigate the predictive utility of PGS for osteoporosis, we evaluated the

model's performance after including PGS in addition to sex and age. In validation cohort I,

there were 1,286 cases of osteoporosis out of 7,609, and in validation cohort II, there were

233 cases of osteoporosis in 1,061 patients (Supplementary Table S5). In validation cohorts

I and II, the AUC values of the baseline model, including sex and age were 0.726 (95% CI:

0.711–0.741) and 0.659 (95% CI: 0.622–0.696), respectively (Supplementary Figure 2A and

Supplementary Table S6). Adding PGS to the model resulted in slight improvements, with

AUC values of 0.728 (95% CI: 0.713–0.743) and 0.664 (95% CI: 0.627–0.701) in validation

cohorts I and II, respectively (Supplementary Figure 2A and Supplementary Table S6).

We assessed the association between the T-score PGS and osteoporosis using

multivariable models in the two validation cohorts (Supplementary Figure 2B and

Supplementary Table S7). A fixed-effect model indicated minimal intercohort heterogeneity

for the PGS effect (I^2 = 0%, Cochran's Q = 0.02, P for heterogeneity = 0.878). Accordingly,

we report the fixed-effect pooled estimate. Each 1.0-unit increase in the normalized PGS was

associated with 12% lower odds of osteoporosis (OR = 0.88, 95% CI: 0.83–0.94, P = 2.77 ×

10^{-5}), indicating an inverse association between the T-score PGS and osteoporosis risk. In

addition, the odds of osteoporosis increased by 7% per year of age (OR = 1.07, 95% CI:

1.07–1.08, P = 3.03 × 10^{-115}), and were 1.84-fold higher in females than in males (OR = 1.84,

95% CI: 1.57–2.17, P = 2.02 × 10^{-13}).

Osteoporosis risk prediction using T-score PGS

For further analysis, individuals in the validation cohorts were stratified into quintiles

using the PGS. In the fixed-effect meta-analysis of the two validation cohorts, individuals in

the lowest PGS quintile (Q1)—which also had the lowest mean T-score (Supplementary

Table S8)—had a significantly increased risk of developing osteoporosis compared to the

intermediate PGS quintile (Q3) (Table 2). Moreover, the OR for Q2 was significantly higher

than that for Q3 (Table 2). In contrast, the highest PGS quintile (Q5)—which had the highest

mean T-score (Supplementary Table S8)—was associated with a significantly lower risk of

osteoporosis than Q3 (Table 2).

Osteoporosis genetic risk stratification by T-score PGS: Joint effects of age group,

sex, and modifiable factors

To evaluate the influence of age and sex on the genetic risk of osteoporosis, we

stratified participants at the clinically relevant threshold of 65 years, as recommended by

osteoporosis guidelines for the Dual-energy X-ray Absorptiometry-based screening.[35] Using

individuals with intermediate (Q2–Q4) PGS as the reference group, we compared the risk of

osteoporosis across the genetic risk categories (Figure 3 and Supplementary Table S9). In

the fixed-effect meta-analysis, younger individuals (<65 years) with a lower genetic risk (Q5)

showed significantly reduced odds of osteoporosis compared with the reference (OR = 0.74,

95% CI: 0.59–0.92, P = 0.006). Among older participants (≥65 years), those with a high

genetic risk (Q1) exhibited significantly increased odds of osteoporosis compared to the

reference (OR = 1.30, 95% CI: 1.04–1.62, P = 0.019). These findings suggest that a low

genetic risk is more detectable in younger individuals, whereas a high genetic risk becomes

evident in those aged ≥65 years.

We then performed additional stratification according to sex. In women, the pattern

was consistent with the overall findings: those with low genetic risk (Q5) had a significantly

reduced odds of osteoporosis in the <65 group (OR = 0.74, 95% CI: 0.57–0.95, P = 0.017),

while those ≥65 years with high genetic risk (Q1) showed increased odds compared with the

reference group (OR = 1.42, 95% CI: 1.08–1.86, P = 0.012). However, in men, no significant

differences in osteoporosis odds were observed across genetic risk categories within age

groups.

Subsequently, we assessed the effects of modifiable lifestyle factors. Stratification

by established risk factors—including obesity, smoking, high alcohol intake, and physical

inactivity—did not show significant modification of genetic risk (Supplementary Figure S3 and

Supplementary Table S10).

Prospective cohort analysis

During the follow-up period, the corresponding person-years of observation for

validation cohorts I and II were 16,226.8 and 1,901.6, respectively. During the follow-up

period, 422 of 4,811 participants in validation cohort I and 116 of 581 in validation cohort II

developed new cases (Supplementary Table S11). In both cohorts, the cumulative incidence

of osteoporosis was highest in the genetic high-risk group (Q1) and lowest in the low-risk

group (Q5), with the incidence rate showing a similar trend (Table 3). In the meta-analysis of

IRR, the high-risk group (Q1) showed a significantly elevated risk compared with the

intermediate group (Q2-Q4), whereas the low-risk group (Q5) showed a significantly reduced

risk (Table 3).

Interaction of age with genetic risk of T-score and osteoporosis

We examined whether the predictive effect of PGS on osteoporosis varied with age.

Interaction terms for age × PGS were tested using logistic regression models with

osteoporosis as the outcome, including sex as a covariate. None of the interaction terms

reached statistical significance, indicating that the effect of PGS on osteoporosis was

consistent across different ages (Supplementary Table S12).

We then assessed the correlation between baseline age and T-score separately by

genetic risk group, comparing each group with the intermediate-risk group (Supplementary

Figure S4). No significant differences were observed in either the high- or low-risk groups,

and the slope of the association did not differ significantly between the groups

(Supplementary Table S13). These results suggest that the PGS was not associated with the

rate of age-related T-score decline.

We next used the fitted age–T-score regression lines to estimate group-specific

mean T-scores at age 20 years as an approximation of peak bone mass. When extrapolating

the linear regression model to age 20 years, the predicted mean T-score differed significantly

by genetic risk group: relative to the intermediate-risk group, the low-risk group showed a

positive deviation, whereas the high-risk group showed a negative deviation (Supplementary

Table S14). Consistent with this pattern, analyses of observed T-scores at baseline among

participants aged 20–44 years (young adult range) showed a modest, non-significant trend

toward lower values in the high-risk group and significantly higher values in the low-risk group

compared with the intermediate-risk group (Table 4). These findings suggest that high-

genetic risk primarily lowers the BMD trajectory from early adulthood, rather than accelerating

age-related bone loss, so that parallel declines over time cause these individuals to reach

the osteoporotic range earlier.

Discussion

Most polygenic models for bone traits have been developed using European

cohorts.[5,9,10] Given ancestry differences, portability across populations remains a key

challenge, despite recent efforts toward cross-ancestry models.[36,37] Although our Japanese-

specific model may not directly integrate into multi-ancestry frameworks, it provides one of

the first large-scale polygenic tools for osteoporosis risk in East Asians and may serve as a

valuable option in this population.

In this study, we developed and validated a Japanese-specific PGS model for

osteoporosis in a large-scale cohort. Given known ancestry differences in allele frequencies,

linkage disequilibrium structure, and environmental exposures, such population-tailored

scores are likely to perform better than PGSs derived exclusively from European cohorts in

East Asian populations. Our GWAS identified three loci—*MBL2, TMEM135*, and *WNT16*—

which have also been reported in previous GWASs in both European and East Asian

populations.[5,9,38,39] The concordance of these loci across populations, together with their

involvement in bone-metabolism pathways,[8] supports the reliability of our GWAS and its use

as a basis for constructing a PGS in East Asians.

The predictive performance of our model (AUC ~0.73) was comparable to that of

European-derived models.[5,10] Our model explained approximately 20–24% of the variance

in QUS-derived T-scores, a proportion consistent with previous large-scale studies using

similar methods.[9] These results highlight the potential clinical utility of a population-specific

polygenic tools for the early identification of osteoporosis risk.

Although no statistically significant interaction between age and PGS was detected

in logistic regression models, subgroup analyses revealed clinically meaningful patterns.

Age-stratified odds ratios indicated that individuals at high genetic risk had an increased

likelihood of osteoporosis in older age, even in the absence of a formal interaction term.

Together with the lack of differences in the slope of the age–T-score association across

genetic risk groups, these findings suggest that the PGS is not strongly associated with the

rate of age-related T-score decline.

Taken together, the observed age-stratified odds ratios and the contrasts in

predicted and observed T-scores in young adults support a model in which high-genetic risk

primarily lowers the bone mass trajectory from early adulthood, rather than accelerating age-

related bone loss. Under this model, parallel age-related declines across PGS groups mean

that individuals at high genetic risk are more likely to cross the osteoporotic threshold earlier

in later life. This interpretation is in line with previous observations that many BMD-associated

genetic variants exert stronger effects during the bone accrual phase in youth,[7] and is

concordant with pediatric data showing that a BMD-related polygenic score is associated

with higher BMD and reduced fracture risk in childhood,[40] as also highlighted by Fiscaletti

and Manousaki.[41]

This interpretation is clinically relevant. Peak bone mass has long-term implications

for osteoporosis development, and individuals with a high genetic risk may inherently have a

lower bone mass established during early adulthood. Therefore, early identification and

intervention before the onset of bone loss may be the most effective. The absence of a

statistical interaction should not be viewed as evidence against clinical relevance; instead,

our findings underscore the importance of age-stratified analyses and large-scale cohorts in

detecting subtle yet meaningful gene-environment dynamics.

This study had some limitations. First, data on prior osteoporosis treatment were

unavailable, and participants undergoing therapy at baseline may not have been excluded.

Second, recruitment was limited to participants from health check-ups and community

support centers in Miyagi and Iwate Prefectures, potentially introducing a health-conscious

selection bias.[20-22] Third, key lifestyle factors (e.g., alcohol use, smoking, and physical

activity) were assessed by self-report, which may have affected accuracy. In addition, most

participants were middle-aged or older, and although lifestyle interventions can increase or

maintain BMD to some extent even in older adults, their effects are generally considered

small [1,42]. This does not argue against the importance of lifestyle, but rather may reflect the

limited plasticity of BMD once peak bone mass has been established. Our findings therefore

support a prevention strategy that combines early identification of genetically susceptible

individuals with lifelong optimization of lifestyle factors.

In conclusion, we established a polygenic score for osteoporosis risk in a Japanese

cohort and validated its performance. Our findings suggest that this score primarily reflects

genetically determined peak bone mass, such that high-risk individuals enter adulthood with

lower BMD levels and, despite similar rates of decline, reach the osteoporotic threshold

earlier. These observations support the use of polygenic information to identify susceptible

individuals at an early stage and to focus bone-preserving lifestyle strategies particularly

before the attainment of peak bone mass. However, further studies are needed to determine

whether PGS-based interventions initiated in childhood or adolescence can reduce the risk

of osteoporosis.

Acknowledgements

This study was supported by the Tohoku Medical Megabank (TMM) Project (Special Account

for the Reconstruction of the Great East Japan Earthquake) of the Ministry of Education,

Culture, Sports, Science and Technology (MEXT) and the Japan Agency for Medical

Research and Development (AMED) under grant number JP23tm0124006. The

supercomputer system in the TMM Project under grant number JP21tm0424601 was used

for data analysis. YOY and AS were supported by the Japan Society for the Promotion of

Science (JSPS) KAKENHI Grant JP23K09696.

Supplementary information

Supplementary information is available with the preprint on medRxiv.

References

1.   Bouvard B, Annweiler C, Legrand E. Osteoporosis in older adults. Joint Bone Spine.

2021;88(3):105135. Epub 20210121. doi: 10.1016/j.jbspin.2021.105135

2.   Mori T, Komiyama J, Fujii T, Sanuki M, Kume K, Kato G, et al. Medical expenditures for

fragility hip fracture in Japan: a study using the nationwide health insurance claims

database. Arch Osteoporos. 2022;17(1):61. Epub 20220411. doi: 10.1007/s11657-022-

01096-8

3.   Zhu X, Bai W, Zheng H. Twelve years of GWAS discoveries for osteoporosis and related

traits: advances, challenges and applications. Bone Res. 2021;9(1):23. Epub 20210429.

doi: 10.1038/s41413-021-00143-3

4.   Abe K, Inage K, Yoshimura K, Sato D, Yamashita K, Yamashita M, et al. Deaths caused

by osteoporotic fractures in Japan: An epidemiological study. J Orthop Sci.

2024;29(6):1477–82. Epub 20231118. doi: 10.1016/j.jos.2023.10.013

5.   Kim SK. Identification of 613 new loci associated with heel bone mineral density and a

polygenic risk score for bone mineral density, osteoporosis and fracture. PLoS One.

2018;13(7):e0200785. Epub 20180726. doi: 10.1371/journal.pone.0200785

6.   Hereford T, Kellish A, Samora JB, Reid Nichols L. Understanding the importance of peak
bone   mass.   JPOSNA.   2024;7:100031.   Epub   20240405.   doi:
10.1016/j.jposna.2024.100031

7.   Medina-Gomez C, Kemp JP, Trajanoska K, Luan J, Chesi A, Ahluwalia TS, et al. Life-
Course Genome-wide Association Study Meta-analysis of Total Body BMD and
Assessment of Age-Specific Effects. Am J Hum Genet. 2018;102(1):88–102. doi:
10.1016/j.ajhg.2017.12.005

8.   Morris JA, Kemp JP, Youlten SE, Laurent L, Logan JG, Chai RC, et al. An atlas of genetic
influences on osteoporosis in humans and mice. Nat Genet. 2019;51(2):258–66. Epub
20181231. doi: 10.1038/s41588-018-0302-x

9.   Forgetta V, Keller-Baruch J, Forest M, Durand A, Bhatnagar S, Kemp JP, et al.
Development of a polygenic risk score to improve screening for fracture risk: A genetic
risk   prediction   study.   PLoS   Med.   2020;17(7):e1003152.   Epub   20200702.   doi:
10.1371/journal.pmed.1003152

10. Lu T, Forgetta V, Keller-Baruch J, Nethander M, Bennett D, Forest M, et al. Improved
prediction of fracture risk leveraging a genome-wide polygenic risk score. Genome Med.
2021;13(1):16. Epub 20210203. doi: 10.1186/s13073-021-00838-6

11. Wu Q, Jung J. Genome-wide polygenic risk score for major osteoporotic fractures in
postmenopausal women using associated single nucleotide polymorphisms. J Transl
Med. 2023;21(1):127. Epub 20230216. doi: 10.1186/s12967-023-03974-2

12. Kim DJ, Kang JH, Kim JW, Cheon MJ, Kim SB, Lee YK, et al. Evaluation of optimal
methods and ancestries for calculating polygenic risk scores in East Asian population.
Sci Rep. 2023;13(1):19195. Epub 20231106. doi: 10.1038/s41598-023-45859-w

13. Lee SH, Lee SW, Ahn SH, Kim T, Lim KH, Kim BJ, et al. Multiple gene polymorphisms
can improve prediction of nonvertebral fracture in postmenopausal women. J Bone Miner
Res. 2013;28(10):2156–64. doi: 10.1002/jbmr.1955

14. Lin YJ, Liang WM, Chiou JS, Chou CH, Liu TY, Yang JS, et al. Genetic predisposition to
bone mineral density and their health conditions in East Asians. J Bone Miner Res.
2024;39(7):929–41. doi: 10.1093/jbmr/zjae078

15.   Prive F, Aschard H, Carmi S, Folkersen L, Hoggart C, O'Reilly PF, et al. Portability of 245

polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups

from the same cohort. Am J Hum Genet. 2022;109(1):12–23. doi:

10.1016/j.ajhg.2021.11.008

16.   Li YM, Peng C, Zhang JG, Zhu W, Xu C, Lin Y, et al. Genetic risk factors identified in

populations of European descent do not improve the prediction of osteoporotic fracture

and bone mineral density in Chinese populations. Sci Rep. 2019;9(1):6086. Epub

20190415. doi: 10.1038/s41598-019-42606-y

17.   Chen JJ, Chen IC, Wei CY, Lin SY, Chen YM. Utilize polygenic risk score to enhance

fracture risk estimation and improve the performance of FRAX in patients with

osteoporosis. Arch Osteoporos. 2023;18(1):147. Epub 20231201. doi: 10.1007/s11657-

023-01357-0

18.   Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, et al. Genetic Risk,

Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med.

2016;375(24):2349–58. Epub 20161113. doi: 10.1056/NEJMoa1605086

19.   Yang YQ, Yu XH, Bo L, Lei SF, Deng FY. Genetic Risk for Osteoporosis and the Benefit

of Adherence to Healthy Lifestyles. Int J Public Health. 2022;67:1605114. Epub 20220913.

doi: 10.3389/ijph.2022.1605114

20.   Kuriyama S, Yaegashi N, Nagami F, Arai T, Kawaguchi Y, Osumi N, et al. The Tohoku

Medical Megabank Project: Design and Mission. J Epidemiol. 2016;26(9):493–511. Epub

20160702. doi: 10.2188/jea.JE20150268

21.   Hozawa A, Tanno K, Nakaya N, Nakamura T, Tsuchiya N, Hirata T, et al. Study Profile of

the Tohoku Medical Megabank Community-Based Cohort Study. J Epidemiol.

2021;31(1):65–76. Epub 20200111. doi: 10.2188/jea.JE20190271

22.   Hozawa A, Nakaya K, Nakaya N, Nakamura T, Kogure M, Hatanaka R, et al. Progress

Report of the Tohoku Medical Megabank Community-based Cohort Study: Study Profile

of the Repeated Center-based Survey During Second Period in Miyagi Prefecture. J

Epidemiol. 2024;34(9):434–43. Epub 20240731. doi: 10.2188/jea.JE20230241

23.   Yasuda J, Kinoshita K, Katsuoka F, Danjoh I, Sakurai-Yageta M, Motoike IN, et al.

550   Genome analyses for the Tohoku Medical Megabank Project towards establishment of

551   personalized healthcare. J Biochem. 2019;165(2):139–58. doi: 10.1093/jb/mvy096

552   24.   Minegishi N, Nishijima I, Nobukuni T, Kudo H, Ishida N, Terakawa T, et al. Biobank

553   Establishment and Sample Management in the Tohoku Medical Megabank Project.

554   Tohoku J Exp Med. 2019;248(1):45–55. doi: 10.1620/tjem.248.45

555   25.   Sakurai-Yageta M, Kumada K, Gocho C, Makino S, Uruno A, Tadaka S, et al. Japonica

556   Array NEO with increased genome-wide coverage and abundant disease risk SNPs. J

557   Biochem. 2021;170(3):399–410. doi: 10.1093/jb/mvab060

558   26.   Sutoh Y, Hachiya T, Otsuka-Yamasaki Y, Komaki S, Minabe S, Ohmomo H, et al. Healthy

559   lifestyle practice correlates with decreased obesity prevalence in individuals with high

560   polygenic risk: TMM CommCohort study. J Hum Genet. 2025;70(1):9–15. Epub

561   20240822. doi: 10.1038/s10038-024-01280-3

562   27.   Loh PR, Kichaev G, Gazal S, Schoech AP, Price AL. Mixed-model association for

563   biobank-scale datasets. Nat Genet. 2018;50(7):906–8. doi: 10.1038/s41588-018-0144-6

564   28.   Tadaka S, Katsuoka F, Ueki M, Kojima K, Makino S, Saito S, et al. 3.5KJPNv2: an allele

565   frequency panel of 3552 Japanese individuals including the X chromosome. Hum

566   Genome Var. 2019;6:28. Epub 20190618. doi: 10.1038/s41439-019-0059-5

567   29.   Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, et al. The

568   mutational constraint spectrum quantified from variation in 141,456 humans. Nature.

569   2020;581(7809):434–43. Epub 20200527. doi: 10.1038/s41586-020-2308-7

570   30.   Boughton AP, Welch RP, Flickinger M, VandeHaar P, Taliun D, Abecasis GR, et al.

571   LocusZoom.js: interactive and embeddable visualization of genetic association study

572   results. Bioinformatics. 2021;37(18):3017–8. doi: 10.1093/bioinformatics/btab186

573   31.   Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-

574   specific haplotype structure and linking correlated alleles of possible functional variants.

575   Bioinformatics. 2015;31(21):3555–7. Epub 20150702. doi: 10.1093/bioinformatics/btv402

576   32.   Sutoh Y, Hachiya T, Otsuka-Yamasaki Y, Komaki S, Minabe S, Ohmomo H, et al. Genetic

577   predisposition for immunoglobulin E production explains atopic risk in children: Tohoku

Medical Megabank cohort study. Am J Hum Genet. 2025;112(8):1852–1863. Epub

20250721. doi: 10.1016/j.ajhg.2025.06.015

33.   Ge T, Chen CY, Ni Y, Feng YA, Smoller JW. Polygenic prediction via Bayesian regression

and continuous shrinkage priors. Nat Commun. 2019;10(1):1776. Epub 20190416. doi:

10.1038/s41467-019-09718-5

34.   Vilhjalmsson BJ, Yang J, Finucane HK, Gusev A, Lindstrom S, Ripke S, et al. Modeling

Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. Am J Hum Genet.

2015;97(4):576–92. doi: 10.1016/j.ajhg.2015.09.001

35.   Ward RJ, Roberts CC, Bencardino JT, Arnold E, Baccei SJ, Cassidy RC, et al. ACR

Appropriateness Criteria® Osteoporosis and Bone Mineral Density. J Am Coll Radiol.

2017;14(5S):S189–S202. doi: 10.1016/j.jacr.2017.02.018

36.   Kelemen M, Vigorito E, Fachal L, Anderson CA, Wallace C. shaPRS: Leveraging shared

genetic effects across traits or ancestries improves accuracy of polygenic scores. Am J

Hum Genet. 2024;111(6):1006–17. Epub 20240503. doi: 10.1016/j.ajhg.2024.04.009

37.   Moreno-Grau S, Vernekar M, Lopez-Pineda A, Mas-Montserrat D, Barrabes M, Quinto-

Cortes CD, et al. Polygenic risk score portability for common diseases across genetically

diverse populations. Hum Genomics. 2024;18(1):93. Epub 20240902. doi:

10.1186/s40246-024-00664-y

38.   Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, et al. A cross-

population atlas of genetic associations for 220 human phenotypes. Nat Genet.

2021;53(10):1415–24. Epub 20210930. doi: 10.1038/s41588-021-00931-x

39.   Lu HF, Hung KS, Chu HW, Wong HS, Kim J, Kim MK, et al. Meta-Analysis of Genome-

Wide Association Studies Identifies Three Loci Associated With Stiffness Index of the

Calcaneus. J Bone Miner Res. 2019;34(7):1275–83. Epub 20190319. doi:

10.1002/jbmr.3703

40.   Mitchell JA, Bradfield J, McCormack SE, Chesi A, Kalkwarf HJ, Lappe JM, et al. The

gSOS Polygenic Score is Associated with Bone Density and Fracture Risk in Childhood.

J Bone Miner Res. 2025. Epub 20251014. doi: 10.1093/jbmr/zjaf149

41.   Fiscaletti M, Manousaki D. Validation of a Polygenic Score for Bone Health-Related
607   Outcomes in Childhood. J Bone Miner Res. 2025. Epub 20251010. doi:
608   10.1093/jbmr/zjaf146
609   42.   Bonjour JP, Gueguen L, Palacios C, Shearer MJ, Weaver CM. Minerals and vitamins in
610   bone health: the potential value of dietary enhancement. Br J Nutr. 2009;101(11):1581–
611   96. Epub 20090401. doi: 10.1017/S0007114509311721
612
613

Table 1. Lead variants identified in the genome-wide association study of QUS-derived T-score in the Japanese population.

rsID (Lead SNP)	CHR	BP	Near Gene	TMM18K-JPAv2							GCST006433						
				EA	NEA	EAF	Beta	SE	*P* value	INFO	EA	NEA	EAF	Beta	SE	*P* value	INFO
rs71032654; rs200903639	10	54,429,192	*MLB2*	TAC	TATATATATATATATATATACAC	0.649	0.091	0.015	**5.70E-10**	0.935	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
rs2451053	11	86,853,548	*TMEM135*	T	C	0.678	-0.088	0.014	**1.10E-09**	0.999	T	C	0.471	-0.043	0.002	**7.70E-97**	0.998
rs10254825	7	120,956,440	*WNT16*	G	A	0.445	0.081	0.014	**8.30E-09**	0.941	G	A	0.395	0.182	0.002	**3.0E-1601**	0.980

Variants were filtered based on minor allele frequency (MAF ≥0.01) and imputation INFO score (≥0.4). Effect alleles (EA) and non-effect alleles (NEA), along with corresponding effect sizes (Beta), from the GCST006433 GWAS summary statistics were re-aligned and recalculated using gnomAD v2.1 (GRCh37) to harmonize allele orientation with the TMM18K-JPAv2 dataset. Bold indicates statistical significance ($P < 5 \times 10^{-8}$).

Abbreviations: *BP,* base position; *CHR*, chromosome; *EAF*, effect allele frequency; *INFO*, imputation quality score; *JPAv2*, Japonica Array version 2；*MBL2*, mannose-binding lectin 2; *n.d.*, not detected; *SE*, standard error; *TMEM135*, transmembrane protein 135; *TMM*, Tohoku Medical Megabank; *WNT16*, Wnt family member 16.

Table 2. Osteoporosis prevalence and odds ratio stratified by PGS quintile in baseline study.

	PGS (quintile)	Number of subjects (n)	Number of cases (n)	Prevalence (%)	OR	95%CI Low	95%CI High	P value	P for trend	Cochran's Q	I² (%)	p_{het}
Validation cohort I (TMM9K-JPAv2, N=7,609)	Q1	1,522	289	19.0	1.24	1.02	1.51	**0.032**		–	–	–
	Q2	1,522	273	17.9	1.17	0.96	1.43	0.116		–	–	–
	Q3	1,521	240	15.8	1.00 (Reference)	–	–	–	**2.37E-04**	–	–	–
	Q4	1,522	263	17.3	1.06	0.87	1.30	0.556		–	–	–
	Q5	1,522	221	14.5	0.86	0.70	1.05	0.142		–	–	–
Validation cohort II (TMM18K-JPANEO, N=1,061)	Q1	213	49	23.0	1.02	0.64	1.62	0.940		–	–	–
	Q2	212	46	21.7	0.89	0.55	1.42	0.615		–	–	–
	Q3	212	49	23.1	1.00 (Reference)	–	–	–	0.490	–	–	–
	Q4	212	45	21.2	0.92	0.57	1.47	0.714		–	–	–
	Q5	212	44	20.8	0.83	0.52	1.33	0.443		–	–	–
Fixed-effect meta-analysis	Q1	–	–	–	1.22	1.07	1.40	**0.003**		0.64	0.0	0.72
	Q2	–	–	–	1.15	1.00	1.31	**0.047**		1.26	0.0	0.53
	Q3	–	–	–	1.00 (Reference)	–	–	–	–	–	–	–
	Q4	–	–	–	1.05	0.92	1.20	0.489		0.35	0.0	0.84
	Q5	–	–	–	0.85	0.74	0.98	**0.027**		0.01	0.0	0.99

Odds ratios for osteoporosis at baseline were estimated using logistic regression adjusted for age and sex. Pooled estimates were obtained using fixed-effects meta-analysis. Bold indicates statistical significance ($P < 0.05$). Abbreviations: *CI*, confidence interval; *I²*, percentage of variation due to heterogeneity; *JPANEO*, Japonica Array NEO; *JPAv2*, Japonica Array version 2; OR, odds ratio; P_{het}, P value for heterogeneity; *PGS*, polygenic score; *TMM*, Tohoku Medical Megabank. Q indicates quintile.

Table 3. Incidence and risk estimates of osteoporosis by PGS-based genetic risk group in the follow-up study.

	Genetic risk [quintile]	n at risk	Cases	Person-years	Cumulative incidence (%)	95%CI Low	95%CI High	Incidence rate (/1,000 PY)	95%CI Low	95%CI High	IRR	95%CI Low	95%CI High	P value	Cochran's Q	I² (%)	P_{het}
Validation cohort I TMM9K-JPAv2 (N=4,811)	High [Q1]	914	116	3032.7	12.7	10.6	15.0	38.2	31.6	45.9	1.45	1.16	1.80	**9.30E-04**	–	–	–
	Intermediate [Q2 - Q4]	2,910	260	9815.6	8.9	7.9	10.0	26.5	23.4	29.9	1.00 (reference)	–	–	–	–	–	–
	Low [Q5]	987	66	3378.5	6.7	5.2	8.4	19.5	15.1	24.9	0.74	0.57	0.97	**0.030**	–	–	–
Validation cohort II TMM18K-JPANEO (N=581)	High [Q1]	115	30	357.4	26.1	18.3	35.1	83.9	56.6	119.8	1.33	0.87	2.03	0.188	–	–	–
	Intermediate [Q2 - Q4]	356	74	1161.1	20.8	16.7	25.4	63.7	50.0	80.0	1.00 (reference)	–	–	–	–	–	–
	Low [Q5]	110	12	383.0	10.9	5.8	18.3	31.3	16.2	54.7	0.51	0.28	0.94	**0.030**	–	–	–
Fixed-effect meta-analysis	High [Q1]	–	–	–	–	–	–	–	–	–	1.42	1.17	1.73	**3.89E-04**	0.12	0.0	0.73
	Intermediate [Q2 - Q4]	–	–	–	–	–	–	–	–	–	1.00 (reference)	–	–	–	–	–	–
	Low [Q5]	–	–	–	–	–	–	–	–	–	0.70	0.54	0.89	**0.004**	1.23	18.6	0.27

IRR for incident osteoporosis during the follow-up period was estimated using logistic regression adjusted for age and sex.

Pooled estimates were obtained using fixed-effect meta-analysis. Bold indicates statistical significance (*P* < 0.05).

Abbreviations: *CI*, confidence interval; *I²*, percentage of variation due to heterogeneity; *IRR*, incidence rate ratios; *JPANEO*,

Japonica Array NEO; *JPAv2*, Japonica Array version 2; P_{het}, P value for heterogeneity; *PGS*, polygenic score; *PY*, person-years; *TMM*, Tohoku Medical Megabank.

Table 4. Differences in observed T-score at baseline (age 20-44, young adult range) for high- and low-generic risk groups versus the intermediate-risk group (Q2–Q4).

overall	Genetic risk [quintile]	n	Observed T-score		Difference in observed T-score vs Intermediate group (group − intermediate)							
			Mean	SD	Mean	SE	95%CI		P value	Cochran's Q	I² (%)	Phet
							Low	High				
Validation cohort I (TMM9K-JPAv2, N=7,609)	High [Q1]	314	-0.831	1.140	-0.135	0.076	-0.283	0.014	**0.038**	–	–	–
	Intermediate [Q2 - Q4]	898	-0.696	1.193	–	–	–	–	–	–	–	–
	Low [Q5]	279	-0.439	1.184	0.257	0.081	0.098	0.417	**0.001**	–	–	–
Validation cohort II (TMM18K-JPANEO, N=1,061)	High [Q1]	48	-0.891	1.031	-0.118	0.186	-0.487	0.251	0.264	–	–	–
	Intermediate [Q2 - Q4]	122	-0.773	1.236	–	–	–	–	–	–	–	–
	Low [Q5]	42	-0.831	1.230	-0.059	0.220	-0.498	0.380	0.605	–	–	–
Fixed-effect meta-analysis	High [Q1]	–	–	–	-0.133	0.070	-0.270	0.005	0.059	0.01	0	0.93
	Low [Q5]	–	–	–	0.219	0.076	0.070	0.369	**0.004**	1.81	44.8	0.18

The differences in observed T-score values at age 20-44 (young adult range) for the high- and low-risk groups compared with the intermediate-risk group (reference). Pooled estimates were obtained using fixed-effect meta-analysis. Bold indicates statistical significance (p < 0.05). Abbreviations: CI, confidence interval; I^2, percentage of variation due to

heterogeneity; *JPANEO*, Japonica Array NEO; *JPAv2*, Japonica Array version 2; P_{het}, P value for heterogeneity; *PGS*,

polygenic score; *TMM*, Tohoku Medical Megabank.

Figure legends

Figure 1. Study design.

Two TMM cohorts (9K and 18K) [20-22] were split by genotyping array—Axiom

Japonica Array v2 (JPAv2) [23,24] and NEO (JPANEO) [25]—into four independent subgroups

(TMM18K-JPAv2, TMM18K-JPANEO, TMM9K-JPAv2, TMM9K-JPANEO). QUS-derived T-

score GWAS was conducted in TMM18K-JPAv2 to derive variant weights; model selection

was performed in TMM9K-JPANEO (Phase 1). The final PGS was evaluated in two

independent validation cohorts: I (TMM9K-JPAv2) and II (TMM18K-JPANEO). Each cohort

underwent (Phase 2) cross-sectional analysis at baseline (excluding participants with missing

T-scores, extreme baseline T-scores (outside the range −4.0 to +4.0 SD), or missing

covariates) and (Phase 3) prospective analysis using follow-up data with additional

exclusions (no follow-up, baseline T-score ≤–2.5 SD, fracture history, self-reported

osteoporosis at follow-up, or extreme baseline T-scores (outside the range −4.0 to +4.0 SD)).

Final sample sizes were 7,609 and 1,061 for cross-sectional, and 4,811 and 581 for

prospective analyses in validation cohorts I and II, respectively. All four subgroups were

independent. Abbreviations: GWAS, genome-wide association study; JPANEO, Japonica

array NEO; JPAv2, Japonica array version 2; PGS, polygenic score; PRS-CS, polygenic risk

score—continuous shrinkage method; P+T, pruning and thresholding method; SD, standard

deviation; TMM, Tohoku Medical Megabank.

Figure 2. Model selection of T-score PGSs.

(A) Discriminative performance (ρ) of 37 candidate models generated using P+T,

LDpred, and PRS-CS methods. PRS-CS (φ = "auto") showed the highest ρ (ρ = 0.147, P =

2.94×10^{-8}). (B) Correlation of PGSs between the model selection cohort (TMM9K-JPANEO)

and validation cohorts I and II (TMM9K-JPAv2 and TMM18K-JPANEO). Scatterplots show

the relationship between normalized PGSs (x-axis) and age- and sex-adjusted T-scores (y-

axis). Dashed lines represent fitted linear regression lines with 95% confidence intervals.

Color gradients indicate sample density. *P* values are from linear regression analyses.

Abbreviations: PGS, polygenic score; PRS-CS, polygenic risk score—continuous shrinkage

method; P+T, pruning and thresholding method.

Figure 3. Osteoporosis prevalence and odds ratio stratified by age-stratified genetic

risk groups.

Participants were stratified by genetic risk (Q1: high, Q2–Q4: intermediate, Q5: low)

and age (<65 or ≥65 years). The individuals with the intermediate [Q2–Q4] PGS group served

as reference. Osteoporosis prevalence (left and middle) and odds ratios (right) at baseline

were estimated using logistic regression adjusted for age and sex, with pooled results via

fixed-effect meta-analysis. Bars indicate 95% confidence intervals. The bar color indicates

the status of genetic risk levels. † indicates a significant trend across genetic risk groups (P

< 0.05). * indicates a statistically significant pooled odds ratio from the fixed-effect meta-

analysis (P < 0.05). Abbreviations: PGS, polygenic score; Q, quintile.

Figure 2. Otsuka-Yamasaki et. al

A

P+T

LDpred

PRS-CS

R^2-cutoff
- 0.2
- 0.4
- 0.6
- 0.8

Spearman ρ

$- \log_{10}(p)$

$- \log_{10}(p)$

$- \log_{10}(\varphi)$

B

Adjusted R^2 = 0.198
P = 7.11×10^{-8}

Adjusted R^2 = 0.237
P = 1.19×10^{-15}

Adjusted R^2 = 0.204
P = 0.001

T-score (adjusted)

Count

Count

Count

Model select cohort

Validation cohort I

Validation cohort II

PGS (normalized)

Figure 3. Otsuka-Yamasaki et. al